Topical antifungals monograph
This article was originally published in The Tan Sheet
Executive Summary
FDA issues final rule in Feb. 8 Federal Register recognizing clotrimazole 1% as safe and effective treatment for athlete's foot (tinea pedis), jock itch (tinea cruris) and ringworm (tinea corporis) under topical antifungal drug products final monograph. Active ingredient in Schering-Plough's Lotrimin AF has been marketed OTC under an NDA since 1989. Agency estimates reg could result in one-time relabeling costs of $50,000-$75,000. FDA originally announced its intention to amend the monograph in May (1"The Tan Sheet" May 28, 2001, p. 3)...
You may also be interested in...
Schering-Plough Lotrimin AF Ingredient Monograph Status Granted
The OTC topical antifungal drug products final monograph will be amended to include clotrimazole 1%, the active ingredient in Schering-Plough Healthcare's Lotrimin AF.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.